FDA Approval of Lenacapavir for Twice-Yearly HIV Prevention

In the ongoing global fight against HIV, the news of FDA approval of Lenacapavir in 2025 has marked an important turning point in public health. The Food and Drug Administration (FDA) officially approving Lenacapavir as a long-acting injectable PrEP not only signifies a major scientific advancement, but also opens up a more convenient and effective prevention option for millions of people at high risk.

For many years, daily oral PrEP has proven effective in reducing the risk of HIV infection, especially among men who have sex with men (MSM), transgender women, and couples with differing HIV statuses. However, the requirement to take medication every day has become a practical barrier for many people, due to forgetting medication, limited access to healthcare services, or the pressure of maintaining continuous treatment. The FDA approval of Lenacapavir – with just 2 injections per year – is seen as the gateway to a new era in sexual health care: optimizing treatment adherence, reducing infection risk, and being more suitable for modern lifestyles.

What is injectable PrEP?

Injectable PrEP is a prevention method developed from the previous model of daily oral PrEP. Currently, PrEP has become an important tool in reducing the rate of HIV transmission, especially among high-risk groups such as MSM, transgender women, and people with HIV-positive partners. Lenacapavir is a PrEP option administered every 6 months that was approved by the FDA in 2025. The standout feature of the drug is its effectiveness lasting up to 6 months, allowing users to receive injections only 2 times a year while maintaining continuous protection against HIV.

The transition from daily oral medication to injections every 6 months is considered the most important advancement in HIV prevention in over a decade, not only reducing the risk of forgetting medication but also increasing long-term treatment adherence, especially for those with time constraints or limited access to healthcare services.

Why is Lenacapavir a significant milestone in HIV prevention?

The FDA approval of Lenacapavir is not merely the introduction of a new medical product, but also a symbol of progress in the global strategy for controlling the HIV epidemic. Lenacapavir belongs to the capsid inhibitor class – a completely new mechanism of action. The drug intervenes in the formation of the protein shell (capsid) of the HIV virus, an essential step for the virus to replicate and spread within the body.

This mechanism differs from previous PrEP drugs like Tenofovir/Emtricitabine, which inhibit the virus's genetic material replication process. Data from multinational clinical trials, including the United States and South Africa, show that in the group receiving Lenacapavir injections, PURPOSE 1 recorded no HIV infections, while PURPOSE 2 recorded 2 infections among 2,179 recipients – a result that surpasses traditional prevention methods.

Efficacy of injectable PrEP based on trial data

Clinical trials related to Lenacapavir show impressive HIV prevention efficacy:

• Group receiving the drug: PURPOSE 1 recorded 0 infections; PURPOSE 2 recorded 2 among 2,179 recipients
• Group not using the drug: new HIV infections were still recorded

These results not only prove the efficacy of Lenacapavir but also confirm the potential of injectable PrEP as a more sustainable and reliable prevention strategy in various contexts.

Notably, the trials included a diverse range of populations, including MSM and transgender women – groups heavily affected by HIV in many parts of the world.

Convenience and usage frequency of Lenacapavir

One of the factors that has made Lenacapavir a global concern is its high convenience.

Users no longer need to take medication every day. Just visiting a healthcare facility every 6 months is enough for continuous protection against HIV.

This method significantly reduces the risk of forgetting medication or inconsistent use – common issues with oral PrEP. At the same time, users do not need to carry medication with them or maintain a daily medication schedule, creating a greater sense of freedom and privacy in personal life.

Who is suitable for injectable PrEP Lenacapavir?

Lenacapavir offers special benefits for the following groups:

• Men who have sex with men (MSM) – a group with high HIV infection rates in many countries.
• Transgender women – especially those with multiple partners or facing difficulties in accessing traditional healthcare services.
• People with HIV-positive partners – even if the partner is on ARV treatment, PrEP still enhances the level of protection.
• People living in areas with limited healthcare access – receiving injections 2 times a year is more convenient than frequent medical check-ups.

Teenagers and young people – a group that may not fully understand the risks or find it difficult to maintain a daily medication habit.

Impact on public health policy

The emergence of Lenacapavir is not only a clinical advancement but also opens up opportunities for reforming public health policies.

Countries with high HIV infection rates in Africa, Asia, and Latin America can integrate injectable PrEP into their national HIV prevention strategies to increase coverage and reduce inequality in healthcare access.

In addition, the implementation of Lenacapavir may support the goal of ending the HIV epidemic by 2030 as outlined by the World Health Organization (WHO) and UNAIDS.

Public communication and community education about injectable PrEP

Medical innovation is only meaningful when the public has access to accurate information.

The rollout of Lenacapavir needs to be accompanied by clear public awareness campaigns about:

• What injectable PrEP is
• Who should use it
• Preparation before injection
• Differences between injectable PrEP and oral PrEP

At the same time, it is important to emphasize that PrEP does not replace condoms, but is an effective complementary measure in a comprehensive prevention strategy.

Hope for ending the HIV epidemic through medical innovation

For many decades, HIV has remained a global health challenge. Although treatment has significantly improved life expectancy and quality of life, new infections continue to occur each year. Lenacapavir is not just an individual choice, but a population-level intervention tool. Injectable PrEP helps significantly reduce the "unprotected period," thereby cutting off the silent transmission chain within communities. If widely implemented, this could be the key factor bringing the goal of ending the HIV epidemic by 2030 closer to reality.

Expert opinions

Many infectious disease and public health experts have evaluated the FDA approval of Lenacapavir as a "historical milestone" in global HIV prevention.

Anthony Fauci, former Director of the National Institute of Allergy and Infectious Diseases in the United States, once noted that injectable PrEP could be the future of HIV control because it eliminates the challenge of daily medication adherence.

The FDA approval of Lenacapavir in 2025 is not just the introduction of a new drug, but the beginning of an era of HIV prevention without the need to take medication every day. With just 2 injections per year, users can be protected for a long time, safely and reliably. This is a groundbreaking advancement, opening up real hope in the journey of controlling and moving toward the end of the global HIV pandemic.

References

• CNN. (June 18, 2025). FDA approves HIV prevention injection used twice a year. https://edition.cnn.com/2025/06/18/health/hiv-lenacapavir-fda-approval
• Gilead Sciences. (June 18, 2025). Gilead announces FDA approval of Yeztugo (lenacapavir) – the first and only HIV prevention option used twice a year. https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection